EDN1 and pulmonary arterial hypertension: Elevated plasma ET-1 levels previously predicted clinical worsening in idiopathic PAH patients on bosentan therapy [22], but it is unknown whether ET-1 levels predict therapeutic response in a broader PAH cohort.